Dr. Ghobadi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
4921 Parkview Pl
7th Fl Siteman Cancer Center
Saint Louis, MO 63110Phone+1 702-413-2096Fax+1 713-794-4902- Is this information wrong?
Education & Training
- Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2009 - 2012
- University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2006 - 2009
- Iran University of Medical SciencesClass of 2001
Certifications & Licensure
- MO State Medical License 2011 - 2025
- TX State Medical License 2012 - 2015
Clinical Trials
- Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma Start of enrollment: 2014 Aug 20
- Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma Start of enrollment: 2015 Feb 20
- Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2015 Aug 21
- Join now to see all
Publications & Presentations
PubMed
- Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Armin Ghobadi, Sairah Ahmed, David B Miklos, Miguel-Angel Perales, Javier Munoz, Warren B Fingrut, Martina Pennisi,...> ;Blood. 2024 Apr 18
- 3 citationsBridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwo...> ;Blood Advances. 2024 Feb 27
- Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.Ghobadi, A., Munoz, J., Westin, J., Locke, F., Miklos, D., Rapoport, A., Perales, M., Reagan, P., McGuirk, J., Jacobson, C., Kersten, M., Avivi, I., Peng, A., Schupp, ...> ;Blood Advances. 2024 Feb 5
- Join now to see all
Journal Articles
- Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published DataFrancesca Ferraro, Peter Westervelt, John F Dipersio, Armin Ghobadi, Leukemia Research
Abstracts/Posters
- Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple MyelomaArmin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lympho...Armin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...Armin Ghobadi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- Secondary Acute Lymphoblastic Leukemia, a Retrospective Analysis from Washington University and Meta-Analysis of Published DataAugust 2018
Press Mentions
- Simple Blood Test Helps Identify Patients Developing Neurotoxic Side EffectsSeptember 8th, 2022
- FDA Grants Orphan Drug Status to CAR-T for T-cell Acute Lymphoblastic LeukemiaMarch 18th, 2022
- Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBLMarch 15th, 2022
- Join now to see all
Hospital Affiliations
- Barnes-Jewish HospitalSaint Louis, Missouri
- Siteman Cancer CenterSaint Louis, Missouri
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: